Sanofi Beheer

Beheer criteriumcontroles 3/4

De CEO Sanofi is Paul Hudson, benoemd in Sep2019, heeft een ambtstermijn van 5.17 jaar. De totale jaarlijkse vergoeding van { bedraagt € 10.57M, bestaande uit 13.2% salaris en 86.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.006% van de aandelen van het bedrijf, ter waarde € 6.52M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 4.6 jaar.

Belangrijke informatie

Paul Hudson

Algemeen directeur

€10.6m

Totale compensatie

Percentage CEO-salaris	13.2%
Dienstverband CEO	5.2yrs
Eigendom CEO	0.006%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	4.6yrs

Recente managementupdates

Geen updates

Recent updates

Analyse CEO-vergoeding

Hoe is Paul Hudson's beloning veranderd ten opzichte van Sanofi's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	€5b
Jun 30 2024	n/a	n/a	€4b
Mar 31 2024	n/a	n/a	€5b
Dec 31 2023	€11m	€1m	€5b
Sep 30 2023	n/a	n/a	€9b
Jun 30 2023	n/a	n/a	€9b
Mar 31 2023	n/a	n/a	€8b
Dec 31 2022	€11m	€1m	€8b
Sep 30 2022	n/a	n/a	€6b
Jun 30 2022	n/a	n/a	€7b
Mar 31 2022	n/a	n/a	€7b
Dec 31 2021	€11m	€1m	€6b
Sep 30 2021	n/a	n/a	€6b
Jun 30 2021	n/a	n/a	€6b
Mar 31 2021	n/a	n/a	€12b
Dec 31 2020	€11m	€1m	€12b
Sep 30 2020	n/a	n/a	€11b
Jun 30 2020	n/a	n/a	€11b
Mar 31 2020	n/a	n/a	€3b
Dec 31 2019	€6m	€433k	€3b

Compensatie versus markt: De totale vergoeding ($USD 11.16M ) Paul } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 4.85M ).

Compensatie versus inkomsten: De vergoeding van Paul is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Paul Hudson (57 yo)

5.2yrs

Tenure

€10,571,822

Compensatie

Mr. Paul Hudson serves as Chief Executive Officer of Sanofi at Hoechst Pakistan Limited (formerly known as sanofi-aventis Pakistan Limited). He has been Chief Executive Officer at Sanofi since September 1,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Hudson	CEO & Director	5.2yrs	€10.57m	0.0056% € 6.5m
François-Xavier Roger	Executive VP & CFO	less than a year	geen gegevens	geen gegevens
Madeleine Roach	Executive VP & Head of Business Operations	1.1yrs	geen gegevens	geen gegevens
Laurent Gilhodes	Principal Accounting Officer and Vice President of Corporate Accounting	no data	geen gegevens	geen gegevens
Josephine Fubara	Chief Science Officer of Consumer Health Care	no data	geen gegevens	geen gegevens
Thomas Larsen	Head of Investor Relations	less than a year	geen gegevens	geen gegevens
Dante Beccaria	Global Compliance Officer & VP	12.6yrs	geen gegevens	geen gegevens
Roy Papatheodorou	Executive VP & General Counsel	2.8yrs	geen gegevens	geen gegevens
Josep Catlla	Head of Communications	no data	geen gegevens	geen gegevens
Pierre Chancel	Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing	20.3yrs	geen gegevens	geen gegevens
Natalie Bickford	Executive VP & Chief People Officer	4.3yrs	geen gegevens	geen gegevens
Marie-Hélène Laimay	Senior Vice President of Audit & Internal Control Assessment	22.5yrs	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

55.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SNW2 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Hudson	CEO & Director	5.1yrs	€10.57m	0.0056% € 6.5m
Jean-François Dehecq	Honorary Chairman	14.5yrs	€4.71m	geen gegevens
Serge Weinberg	Honorary Chairman	1.5yrs	€324.96k	geen gegevens
Patrick Kron	Independent Director	10.5yrs	€175.75k	0.000080% € 92.4k
Lise Kingo	Independent Director	4.6yrs	€148.25k	0.000080% € 92.4k
Frederic Oudea	Independent Chairman	1.5yrs	€573.52k	0.000080% € 92.4k
Fabienne Lecorvaisier	Independent Director	11.5yrs	€156.50k	0.000080% € 92.4k
Gilles Schnepp	Independent Director	2.9yrs	€175.75k	0.000080% € 92.4k
Rachel Duan	Independent Director	4.6yrs	€145.50k	0.000080% € 92.4k
Barbara Lavernos	Director	3.6yrs	€134.50k	0.000080% € 92.4k
Christophe Babule	Director	5.8yrs	€134.50k	0.000080% € 92.4k
Wolfgang Laux	Employee Representative Director	3.6yrs	€107.00k	0.00031% € 357.9k

4.6yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SNW2 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).

Sanofi Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Recent updates

Frantz Law Group Files Oceanside Unified School District Lawsuit Against Eli Lily, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark, and Optum RX for Insulin Pricing Scheme

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Sanofi Announces Beyfortus (Nirsevimab) to Be Broadly Available for Babies Born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon This Fall

Sanofi Reportedly in Talks with French Government over Opella Sale

Clayton, Dubilier & Rice Reportedly Nears €15 Billion Deal for Sanofi Consumer Health Unit

Sanofi Healthcare Bidders Reportedly Revising Offers over Talc Concerns

Sanofi Reportedly Seeks Revised Proposals for Opella

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Sanofi to Report Q2, 2025 Results on Jul 31, 2025

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Sanofi Announces Tolebrutinib Meet Primary Endpoints in HERCULES Phase 3 Study

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd